Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2, Open-Label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of SNB-101, in Extensive Stage Small Cell Lung Cancer

Next Previous
Trial Profile

A Phase 1b/2, Open-Label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of SNB-101, in Extensive Stage Small Cell Lung Cancer

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 12 Mar 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SNB 101 (Primary)
  • Indications Small cell lung cancer
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Acronyms SNB-101-101
  • Sponsors SN BioScience

Most Recent Events

  • 01 Mar 2026 Status changed from not yet recruiting to recruiting.
  • 08 Feb 2026 Status changed from planning to not yet recruiting.
  • 23 Dec 2025 According to the SN BioScience Media Release, a regulatory protocol review is currently underway in Europe for phase 2 trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top